Intensive statin therapy stabilizes C-reactive protein, but not chemokine in stable coronary artery disease treated with an everolimus-eluting stent

Hiroaki Sukegawa, Yuichiro Maekawa, Shinsuke Yuasa, Atsushi Anzai, Masaki Kodaira, Makoto Takei, Fumiya Sano, Ikuko Ueda, Takashi Kawakami, Kentaro Hayashida, Takashi Kohno, Shun Kosaka, Takayuki Abe, Keiichi Fukuda

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

BACKGROUND: Besides its potent plasma cholesterol-lowering activity, statin treatment has several other important effects, including lowering high-sensitive C-reactive protein (hs-CRP), levels, and stabilizing risk factors of atherosclerosis, thereby reducing the risk of cardiovascular events. Our aim in this study was to identify how intensive statin therapy can affect plasma levels of inflammatory markers over the long term. METHODS AND RESULTS: We used a prospective, randomized, open blinded-endpoint design. A total of 30 patients with stable coronary artery disease treated with everolimus-eluting stent implantation were randomized to receive rosuvastatin 2.5 (standard therapy group) or 10 mg (intensive therapy group) for 12 months. Plasma levels of hs-CRP, pentraxin-3, monocyte chemoattractant protein-1, and CXC chemokine ligand 4 were measured after a percutaneous coronary intervention, at 1, 3, 6, 9, and 12 months. Levels of LDL cholesterol (LDL-C) and HDL cholesterol were also measured. We investigated short-term and long-term clinical outcomes. After 12 months of therapy, the intensive therapy group had lower levels of LDL-C than the standard therapy group. Plasma levels of hs-CRP largely fluctuated in the standard therapy group, whereas they were stable in the intensive therapy group during the follow-up period. There were no significant differences in serum pentraxin-3, monocyte chemoattractant protein-1, and CXC chemokine ligand 4 levels, or in the incidence of any clinical adverse events, between the standard and the intensive therapy groups. CONCLUSION: Intensive rosuvastatin therapy stabilizes hs-CRP levels, but not chemokine levels, besides lowering LDL-C levels. Thus, this therapy may inhibit the progression of atherosclerosis by stably inhibiting the inflammatory cascade.

Original languageEnglish
JournalCoronary Artery Disease
DOIs
Publication statusAccepted/In press - 2016 Apr 21

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Group Psychotherapy
Chemokines
C-Reactive Protein
Stents
Coronary Artery Disease
LDL Cholesterol
CXC Chemokines
Chemokine CCL2
Therapeutics
Atherosclerosis
Ligands
Percutaneous Coronary Intervention
Everolimus
HDL Cholesterol
Cholesterol
Incidence
Serum

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Intensive statin therapy stabilizes C-reactive protein, but not chemokine in stable coronary artery disease treated with an everolimus-eluting stent. / Sukegawa, Hiroaki; Maekawa, Yuichiro; Yuasa, Shinsuke; Anzai, Atsushi; Kodaira, Masaki; Takei, Makoto; Sano, Fumiya; Ueda, Ikuko; Kawakami, Takashi; Hayashida, Kentaro; Kohno, Takashi; Kosaka, Shun; Abe, Takayuki; Fukuda, Keiichi.

In: Coronary Artery Disease, 21.04.2016.

Research output: Contribution to journalArticle

Sukegawa, Hiroaki ; Maekawa, Yuichiro ; Yuasa, Shinsuke ; Anzai, Atsushi ; Kodaira, Masaki ; Takei, Makoto ; Sano, Fumiya ; Ueda, Ikuko ; Kawakami, Takashi ; Hayashida, Kentaro ; Kohno, Takashi ; Kosaka, Shun ; Abe, Takayuki ; Fukuda, Keiichi. / Intensive statin therapy stabilizes C-reactive protein, but not chemokine in stable coronary artery disease treated with an everolimus-eluting stent. In: Coronary Artery Disease. 2016.
@article{cd979e4b66614b638e554f93b1784b48,
title = "Intensive statin therapy stabilizes C-reactive protein, but not chemokine in stable coronary artery disease treated with an everolimus-eluting stent",
abstract = "BACKGROUND: Besides its potent plasma cholesterol-lowering activity, statin treatment has several other important effects, including lowering high-sensitive C-reactive protein (hs-CRP), levels, and stabilizing risk factors of atherosclerosis, thereby reducing the risk of cardiovascular events. Our aim in this study was to identify how intensive statin therapy can affect plasma levels of inflammatory markers over the long term. METHODS AND RESULTS: We used a prospective, randomized, open blinded-endpoint design. A total of 30 patients with stable coronary artery disease treated with everolimus-eluting stent implantation were randomized to receive rosuvastatin 2.5 (standard therapy group) or 10 mg (intensive therapy group) for 12 months. Plasma levels of hs-CRP, pentraxin-3, monocyte chemoattractant protein-1, and CXC chemokine ligand 4 were measured after a percutaneous coronary intervention, at 1, 3, 6, 9, and 12 months. Levels of LDL cholesterol (LDL-C) and HDL cholesterol were also measured. We investigated short-term and long-term clinical outcomes. After 12 months of therapy, the intensive therapy group had lower levels of LDL-C than the standard therapy group. Plasma levels of hs-CRP largely fluctuated in the standard therapy group, whereas they were stable in the intensive therapy group during the follow-up period. There were no significant differences in serum pentraxin-3, monocyte chemoattractant protein-1, and CXC chemokine ligand 4 levels, or in the incidence of any clinical adverse events, between the standard and the intensive therapy groups. CONCLUSION: Intensive rosuvastatin therapy stabilizes hs-CRP levels, but not chemokine levels, besides lowering LDL-C levels. Thus, this therapy may inhibit the progression of atherosclerosis by stably inhibiting the inflammatory cascade.",
author = "Hiroaki Sukegawa and Yuichiro Maekawa and Shinsuke Yuasa and Atsushi Anzai and Masaki Kodaira and Makoto Takei and Fumiya Sano and Ikuko Ueda and Takashi Kawakami and Kentaro Hayashida and Takashi Kohno and Shun Kosaka and Takayuki Abe and Keiichi Fukuda",
year = "2016",
month = "4",
day = "21",
doi = "10.1097/MCA.0000000000000375",
language = "English",
journal = "Coronary Artery Disease",
issn = "0954-6928",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Intensive statin therapy stabilizes C-reactive protein, but not chemokine in stable coronary artery disease treated with an everolimus-eluting stent

AU - Sukegawa, Hiroaki

AU - Maekawa, Yuichiro

AU - Yuasa, Shinsuke

AU - Anzai, Atsushi

AU - Kodaira, Masaki

AU - Takei, Makoto

AU - Sano, Fumiya

AU - Ueda, Ikuko

AU - Kawakami, Takashi

AU - Hayashida, Kentaro

AU - Kohno, Takashi

AU - Kosaka, Shun

AU - Abe, Takayuki

AU - Fukuda, Keiichi

PY - 2016/4/21

Y1 - 2016/4/21

N2 - BACKGROUND: Besides its potent plasma cholesterol-lowering activity, statin treatment has several other important effects, including lowering high-sensitive C-reactive protein (hs-CRP), levels, and stabilizing risk factors of atherosclerosis, thereby reducing the risk of cardiovascular events. Our aim in this study was to identify how intensive statin therapy can affect plasma levels of inflammatory markers over the long term. METHODS AND RESULTS: We used a prospective, randomized, open blinded-endpoint design. A total of 30 patients with stable coronary artery disease treated with everolimus-eluting stent implantation were randomized to receive rosuvastatin 2.5 (standard therapy group) or 10 mg (intensive therapy group) for 12 months. Plasma levels of hs-CRP, pentraxin-3, monocyte chemoattractant protein-1, and CXC chemokine ligand 4 were measured after a percutaneous coronary intervention, at 1, 3, 6, 9, and 12 months. Levels of LDL cholesterol (LDL-C) and HDL cholesterol were also measured. We investigated short-term and long-term clinical outcomes. After 12 months of therapy, the intensive therapy group had lower levels of LDL-C than the standard therapy group. Plasma levels of hs-CRP largely fluctuated in the standard therapy group, whereas they were stable in the intensive therapy group during the follow-up period. There were no significant differences in serum pentraxin-3, monocyte chemoattractant protein-1, and CXC chemokine ligand 4 levels, or in the incidence of any clinical adverse events, between the standard and the intensive therapy groups. CONCLUSION: Intensive rosuvastatin therapy stabilizes hs-CRP levels, but not chemokine levels, besides lowering LDL-C levels. Thus, this therapy may inhibit the progression of atherosclerosis by stably inhibiting the inflammatory cascade.

AB - BACKGROUND: Besides its potent plasma cholesterol-lowering activity, statin treatment has several other important effects, including lowering high-sensitive C-reactive protein (hs-CRP), levels, and stabilizing risk factors of atherosclerosis, thereby reducing the risk of cardiovascular events. Our aim in this study was to identify how intensive statin therapy can affect plasma levels of inflammatory markers over the long term. METHODS AND RESULTS: We used a prospective, randomized, open blinded-endpoint design. A total of 30 patients with stable coronary artery disease treated with everolimus-eluting stent implantation were randomized to receive rosuvastatin 2.5 (standard therapy group) or 10 mg (intensive therapy group) for 12 months. Plasma levels of hs-CRP, pentraxin-3, monocyte chemoattractant protein-1, and CXC chemokine ligand 4 were measured after a percutaneous coronary intervention, at 1, 3, 6, 9, and 12 months. Levels of LDL cholesterol (LDL-C) and HDL cholesterol were also measured. We investigated short-term and long-term clinical outcomes. After 12 months of therapy, the intensive therapy group had lower levels of LDL-C than the standard therapy group. Plasma levels of hs-CRP largely fluctuated in the standard therapy group, whereas they were stable in the intensive therapy group during the follow-up period. There were no significant differences in serum pentraxin-3, monocyte chemoattractant protein-1, and CXC chemokine ligand 4 levels, or in the incidence of any clinical adverse events, between the standard and the intensive therapy groups. CONCLUSION: Intensive rosuvastatin therapy stabilizes hs-CRP levels, but not chemokine levels, besides lowering LDL-C levels. Thus, this therapy may inhibit the progression of atherosclerosis by stably inhibiting the inflammatory cascade.

UR - http://www.scopus.com/inward/record.url?scp=84964211345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964211345&partnerID=8YFLogxK

U2 - 10.1097/MCA.0000000000000375

DO - 10.1097/MCA.0000000000000375

M3 - Article

JO - Coronary Artery Disease

JF - Coronary Artery Disease

SN - 0954-6928

ER -